“Every oncologist, every researcher, every IRB has got to know about that study.” @DrMaurieMarkman, on why LACC tops his ranking of landmark gynecologic oncology trials on Double Blind. Watch: youtube.com/watch?v=4KcWCXiR…

Tune in tomorrow as @DrArturoAI takes over @cancernetwrk live from #ESMO26! He will be breaking down cutting-edge AI breakthroughs in oncology, from digital pathology and foundation models to LLM-assisted clinical decision support. Catch the coverage from 1 PM to 4 PM CEST (7 AM to 10 AM EST)! #CNRealtimeReport

We asked Adam Olson, MD (@AdamOlsonMD), what the biggest misconception of brachytherapy in cancer care is! Look for more coverage of the @UPMCHillmanCC Radiation Oncology Symposium on our website in the weeks to come. #RadOnc #oncology #cancer #brachytherapy

What role does brachytherapy play in cancer care? We asked Bhanu Prasad Venkatesulu, MBBS, MD (@BhanuPr92961213)! Stay tuned for more! #RadOnc #pcsm #gyncsm #oncology #cancer

What is the biggest advancement for radiopharmaceuticals in the past year? Ravi Patel, MD, PhD (@RPatelMDPHD), let us know his thoughts at the @UPMCHillmanCC Radiation Oncology Symposium. Stay tuned for more! #RadOnc #oncology #cancer #pcsm

Low-dose radiation treatment for osteoarthritis has spread across the US in recent years. Tyler J. Wilhite, MD, spoke about just this at the @UPMCHillmanCC Radiation Oncology Symposium! Stay tuned for more! #RadiationTherapy #RadOnc #LowDoseRadiation

The workshops at the 2026 @UPMCHillmanCC Radiation Oncology Symposium will help radiation oncologists feel confident in bringing new services to their patients! We just wrapped up our conversation with Parul N. Barry, MD, FACRO (@pnbarry). #RadOnc #Oncology #cancer

Training covered board prep and tumor boards. It didn't cover finding a mentor, getting published, or negotiating a contract. Careers Across the Care Team: 3 free sessions at #SABCS26, Dec 9 to 11, 12 to 1 PM CT. Register: hubs.li/Q04C4cwc0

We are live at the 2026 @UPMCHillmanCC Radiation Oncology Symposium!   Stay tuned for snippets from our conversations at the meeting!   Up first: Heath Skinner, MD, PhD (@HSkinnerMDPhD)   #RadOnc #Oncology #cancer

🚨@FDADrugs provides traditional approval to embrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in unresectable or metastatic TMB-H solid tumors. 🔗cancernetwork.com/view/fda-a…

Risvutatug rezetecan yielded a 61% ORR at 8 mg/kg vs 32% at 6 mg/kg in patients with relapsed extensive-stage small cell lung cancer in the phase 1b dose-optimization portion of the EMBOLD PanTumour-101 trial. hubs.li/Q04C0zlJ0 #SCLC #lcsm #oncology #cancer

🚨6 breast cancer trials to watch at #ESMO26 from leading voices including @ErikaHamilton9 @HundalJasmin and Nusrat Jahan, MD 🔗cancernetwork.com/view/from-… #BCSM @myESMO

Real-world data in @JCOOP_ASCO evaluated 9141 US patients with metastatic HSPC and showed that ARPI doublets (abiraterone, apalutamide, enzalutamide) offer superior PFS compared with docetaxel doublets, with similar OS observed across all regimens. ➡️ ARPI doublets significantly reduced the risk of metastatic CRPC progression or death compared with docetaxel doublets (abiraterone: aHR, 0.60; apalutamide: aHR, 0.64; enzalutamide: aHR, 0.57). ➡️ OS rates were comparable across all doublet regimens, with no significant differences observed among individual ARPIs. ➡️ Patients treated with ARPI doublets had a lower risk of progressing to metastatic disease and a delayed time to initiating a new treatment. #pcsm #OncX #mHSPC

🎙️ In a special edition of #OncologyOnTheGo, @MJFzeta and @CohenAd_MMdoc discussed the evolving cellular therapy landscape in multiple myeloma. Listen as they cover updated findings from CARTITUDE-2, strategies for mitigating late toxicities, and other key considerations in multiple myeloma care: hubs.li/Q04BZhh-0 #mmsm

Still catching up on this year's hematology data? Marc Braunstein, MD, PhD, and Sofia Zahid, MD, break down the ASCO 2026 abstracts most likely to change practice across myeloma, leukemia, and lymphoma. Read here: hubs.li/Q04rZvMq0

Vilamakitug, an investigational anti–IL-1α antibody, met its prespecified 12-month overall survival threshold when added to trifluridine/tipiracil in refractory metastatic colorectal cancer. hubs.li/Q04BQ7Dn0 #crcsm #ColorectalCancer #oncology #cancer

🎧 Should patients wait months for mental health support after a cancer diagnosis? Daniel C. McFarland, DO, and @ramsedhom , explain how co-located teams and warm handoffs meet distress in real time. cancernetwork.com/view/psych… #OncTwitter #psychoonc #PalliativeCare